Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.56 |
| ▸ | PKM | P14618 | 1/20 | 0.56 |
| ▸ | HTR4 | Q13639 | 7/20 | 0.49 |
| ▸ | HTR3A | P46098 | 4/20 | 0.49 |
| ▸ | IL1B | P01584 | 2/20 | 0.46 |
| ▸ | P2RX7 | Q99572 | 2/20 | 0.46 |
| ▸ | TP53 | P04637 | 5/20 | 0.45 |
| ▸ | UTS2R | Q9UKP6 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 4/20 | 0.44 |
| ▸ | MEN1 | O00255 | 2/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.44 |
| ▸ | PARP1 | P09874 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16827187 | 0.86 | HTR4 (0.43) | KDM4EPKMHTR4HTR3AIL1B | |
| SCHEMBL18171071 | 0.85 | HTR4 (0.58) | HTR4HTR3A | |
| SCHEMBL19867073 | 0.84 | KDM4E (0.47) | KDM4EPKM | |
| SCHEMBL16827148 | 0.84 | HTR4 (0.60) | HTR4HTR3A | |
| SCHEMBL16827092 | 0.83 | HTR4 (0.49) | HTR4HTR3A | |
| SCHEMBL16827070 | 0.83 | IL1B (0.45) | HTR4IL1BP2RX7PARP1 | |
| SCHEMBL16827100 | 0.83 | HTR4 (0.51) | HTR4HTR3A | |
| SCHEMBL16827093 | 0.82 | HDAC8 (0.46) | IL1BP2RX7PARP1 | |
| SCHEMBL6980865 | 0.82 | KDM4E (0.61) | KDM4EPKMHTR4HTR3ATP53 | |
| SCHEMBL16827177 | 0.82 | HTR4 (0.50) | HTR4HTR3A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9951045-B2 | Indazole compounds as 5-HT4 receptor agonists | SUVEN LIFE SCIENCES LIMITED (IN) | 2018-04-24 | — | — | US | disclosed |
| US-9951045-B2 | Indazole compounds as 5-HT4 receptor agonists | SUVEN LIFE SCIENCES LIMITED (IN) | 2018-04-24 | — | — | US | disclosed |
| EP-3099675-B1 | INDAZOLE COMPOUNDS AS 5-HT4 RECEPTOR AGONISTS | SUVEN LIFE SCIENCES LTD (IN) | 2018-02-14 | — | — | EP | disclosed |
| EP-3099675-A1 | INDAZOLE COMPOUNDS AS 5-HT4 RECEPTOR AGONISTS | Suven Life Sciences Limited (IN) | 2016-12-07 | — | — | EP | disclosed |
| US-20160311797-A1 | INDAZOLE COMPOUNDS AS 5-HT4 RECEPTOR AGONISTS | SUVEN LIFE SCIENCES LIMITED (IN) | 2016-10-27 | — | — | US | disclosed |
| US-20160311797-A1 | INDAZOLE COMPOUNDS AS 5-HT4 RECEPTOR AGONISTS | SUVEN LIFE SCIENCES LIMITED (IN) | 2016-10-27 | — | — | US | disclosed |
| WO-2015092804-A1 | INDAZOLE COMPOUNDS AS 5-HT4 RECEPTOR AGONISTS | SUVEN LIFE SCIENCES LIMITED (IN) | 2015-06-25 | — | — | WO | disclosed |
| WO-2015092804-A1 | INDAZOLE COMPOUNDS AS 5-HT4 RECEPTOR AGONISTS | SUVEN LIFE SCIENCES LIMITED (IN) | 2015-06-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160311797-A1 | INDAZOLE COMPOUNDS AS 5-HT4 RECEPTOR AGONISTS | HTR4, HTR5A, HTR1A | KDM4E 1816/4885PKM 2565/4885HTR4 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.